Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of PSMA-UCAR T in Refractory CRPC
NCT06895811Phase 1Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Universal BCMA-CD19 CAR-T in prostate cancer (PCa), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Adverse Events assessed by CTCAE v5.0 at 6 months, Cytokine Release Syndrome grading at 6 months and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
Universal BCMA-CD19 CAR-T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06895811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895811.